Skip to main content Back to Top


Orphenadrine Citrate Injection

Products Affected - Description

    • Orphenadrine Citrate solution for injection, Akorn, 30 mg/mL, 2 mL vial, 10 count, NDC 17478-0538-02
    • Orphenadrine Citrate solution for injection, Hikma, 30 mg/mL, 2 mL vial, 10 count, NDC 00641-6182-10

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • Teva discontinued orphenadrine in November 2018.
    • Akorn did not provide a reason for the shortage.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Hikma has orphenadrine 30 mg/mL 2 mL vials on allocation.
    • Akorn has orphenadrine 30 mg/mL 2 mL vials on allocation with the next estimated release date in mid- to late-October 2019.


Updated September 24, 2019 by Rachael Freeman, PharmD, BCPS. Created September 17, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins